HOPA Corner

Katie O’Reilly, PharmD, BCOP

Katie O’Reilly, PharmD, BCOP, provides an update on the current and emerging treatment landscape in small cell lung cancer (SCLC), including an overview of immunotherapy in SCLC and the research supporting its use in limited-stage and extensive-stage settings.

Mind Over Metastases: Navigating Central Nervous System Involvement in Solid Tumors

Kelly Fritz, PharmD, BCOP; Sara deHoll, PharmD, BCOP

Central nervous system involvement in patients diagnosed with solid tumors is common. Kelly Fritz, PharmD, BCOP, and Sara deHoll, PharmD, BCOP, present a review of the treatments for intracranial metastases and leptomeningeal disease, including sequencing and timing of therapies and symptom management.

Don’t Stop Believing—Putting the Person Back Into Practice

Robert Mancini, PharmD, BCOP, FHOPA

Robert Mancini, PharmD, BCOP, FHOPA, was installed as the 2025 HOPA president at the HOPA conference in April. In outlining his priorities and plans for his tenure, he enthusiastically pledges to “start the wave!”

Advancing Merkel-Cell Carcinoma Treatment With Immunotherapy

Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin cancer with rising incidence globally.

DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist’s Guide to Evidence and Integration

Bispecific T-cell engagers (BiTEs) are not new to the hematology treatment landscape, but they are now being investigated in solid tumors. One promising avenue is Delta-like ligand 3 (DLL3)-targeting BiTEs in extensive stage small-cell lung cancer (SCLC).

Checkpoint Inhibitors: Changing Colorectal Cancer Treatment

Immune checkpoint inhibitors (ICIs) have altered the management of several cancers, including a subset of colorectal cancers (CRCs) characterized by mismatch repair deficiency and microsatellite instability (MSI).

505(b)(2) Drugs: New Chaos for Infusion Centers

As oncology pharmacists navigate the ever-evolving therapeutic landscape, regulatory realities pose operational challenges. Scott A. Soefje and Clayton C. Irvine discuss the intricacies of the 505(b)(2) drug approval pathway and its implications on practice management.

The Crossroad of Social Determinants of Health and Inequalities in Hematologic Malignancies

By Cara Guglielmon

Iman Ahmed, PharmD, BCOP, unpacks the evidence for what’s actually contributing to health inequities in hematologic malignancies, and how pharmacists can mitigate these disparities.

Embracing Equity: The Evolving Role of HOPA in Advancing Fairness, Access, and Representation

HOPA establishes the infrastructure for the task force committed to social justice and practical change within the organization to ensure that healthcare systems value diverse perspectives of healthcare providers and honor lived experiences of patients as we strive for the best outcomes.

Pursuing Equity: A Strategic Approach to Improving Diversity, Equity, and Inclusion as an Organizational Priority for the Hematology/Oncology Pharmacy Association

Maurice D. Alexander, PharmD; Larry W. Buie, PharmD; Kamakshi V. Rao, PharmD; Eric Chow, PharmD; Ashley Chen, PharmD; Marcus Autry, PharmD, et al.

Healthcare-serving organizations, such as the Hematology/Oncology Pharmacy Association (HOPA), have commitments to their membership and the communities they serve. HOPA encompasses nearly 4000 oncology pharmacy professionals and has identified diversity, equity, and inclusion (DEI) as strategic priorities. The authors describe an approach for devising recommendations that ultimately inform organizational strategy for improving DEI within HOPA.

April 2026 Vol 16, No 2

View the Latest Issue

HOPA Corner

April 2026 Vol 16, No 2

Subscribe Today!

I'd like to receive: